About Olema Pharmaceuticals, Inc.
https://www.olema.comOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
CEO
Sean P. Bohen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 90
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:6.84M
Value:$196.9M
PARADIGM BIOCAPITAL ADVISORS LP
Shares:6.79M
Value:$195.47M
BVF INC/IL
Shares:5.3M
Value:$152.36M
Summary
Showing Top 3 of 140
About Olema Pharmaceuticals, Inc.
https://www.olema.comOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $45.88M ▼ | $-42.22M ▲ | 0% | $-0.49 ▲ | $-42.17M ▲ |
| Q2-2025 | $0 | $47.86M ▲ | $-43.78M ▼ | 0% | $-0.51 ▼ | $-47.73M ▼ |
| Q1-2025 | $0 | $34.87M ▼ | $-30.39M ▲ | 0% | $-0.36 ▲ | $-34.74M ▲ |
| Q4-2024 | $0 | $36.77M ▼ | $-33.57M ▲ | 0% | $-0.57 ▲ | $-36.65M ▲ |
| Q3-2024 | $0 | $37.62M | $-34.55M | 0% | $-0.6 | $-37.53M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $328.96M ▼ | $352.45M ▼ | $44.97M ▲ | $307.49M ▼ |
| Q2-2025 | $361.91M ▼ | $382M ▼ | $36.77M ▲ | $345.24M ▼ |
| Q1-2025 | $392.71M ▼ | $409.64M ▼ | $26.19M ▼ | $383.45M ▼ |
| Q4-2024 | $434.09M ▲ | $450.98M ▲ | $42.02M ▲ | $408.96M ▲ |
| Q3-2024 | $214.76M | $230.17M | $31.26M | $198.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-42.22M ▲ | $-34.53M ▼ | $17.27M ▼ | $41K ▲ | $-17.21M ▼ | $-34.53M ▼ |
| Q2-2025 | $-43.78M ▼ | $-29.88M ▲ | $34.23M ▲ | $-2.52M ▼ | $1.83M ▲ | $-29.88M ▲ |
| Q1-2025 | $-30.39M ▲ | $-43.98M ▼ | $-45.08M ▲ | $222K ▼ | $-88.84M ▼ | $-43.98M ▼ |
| Q4-2024 | $-33.57M ▲ | $-26.28M ▲ | $-114.42M ▼ | $244.3M ▲ | $103.59M ▲ | $-26.28M ▲ |
| Q3-2024 | $-34.55M | $-27.02M | $45.92M | $92K | $19M | $-27.02M |
CEO
Sean P. Bohen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 90
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:6.84M
Value:$196.9M
PARADIGM BIOCAPITAL ADVISORS LP
Shares:6.79M
Value:$195.47M
BVF INC/IL
Shares:5.3M
Value:$152.36M
Summary
Showing Top 3 of 140